Happy Thursday! Nvidia just dropped its highly anticipated Q2 earnings, and the results are more than just impressive. However, the real story isn’t just in the numbers, it’s in what those numbers signal. Read on for all the insights and analysis, and where shares could be headed next.

Also, the massive rally since April has investors full of confidence; however, Wall Street veterans know that when things get this comfortable, it’s time to pay attention. Read on to see the market signals and why now could be the calm before the big storm.

Plus, if you are interested in a cutting-edge pharmaceutical company that’s on the verge of filing a new drug application, check out today’s sponsor.

In Today's Edition

• MARKET RECAP

• MARKET HEATMAP

• FIVE ZINGERS

• MARKET HISTORY

• ONE FOR THE ROAD

Nvidia Reports Q2 Earnings: Here’s Everything You Need To Know + Jensen Huang Says 'AI Race Is On'

The wait is over. Nvidia released its Q2 earnings report on Wednesday and gave investors a lot to cheer about as the company posted results that topped Wall Street’s expectations.

But the real story isn’t just in the numbers, it’s in what those numbers signal: a seismic shift in the AI landscape. With demand skyrocketing for its next-gen Blackwell platform and a jaw-dropping $60 billion share buyback authorization, Nvidia is not just participating in the AI race — it’s setting the pace.

Read on for all the insights and analysis, and where shares could be headed next.

Reviva Pharmaceuticals Getting Closer To NDA For Schizophrenia Drug

Reviva Pharmaceuticals Inc. (NASDAQ: RVPH), a pharmaceutical company with a late-stage asset that aims to commercialize therapeutics for diseases with unmet medical needs, is getting closer to filing a new drug application with the U.S. Food and Drug Administration for brilaroxazine, its once-daily, serotonin-dopamine signaling modulator drug for treating schizophrenia.

The drug has successfully completed phase 3 trials and a one-year open label extension (OLE) trial, demonstrating statistically significant reductions in major symptoms and a well-tolerated safety profile. Not only did the drug reduce the positive and negative symptoms of this disease, but it also resulted in an improvement in patient adherence, a big problem with schizophrenia. Next up: an NDA application likely in the second quarter of 2026. To learn more about Reviva Pharmaceutical, click here.

This is a paid ad. Please see 17b disclosure here for more information.

Yesterday: U.S. indexes finished higher as the S&P 500 closed at a new record on Wednesday. It was a relatively quiet session as investors eagerly awaited earnings results from Nvidia, which experts say can make or break the current run. Bond markets saw short-term yields decline, with 2- and 10-year notes down two basis points, while the 30-year yield held flat, extending the recent steepening trend in the yield curve. Market focus stayed political as the White House reportedly seeks more influence over regional Fed appointments. Comments from New York Fed President Williams kept rate cut expectations in play ahead of key remarks from Governor Waller on Thursday. Oil and gold prices gained, and the dollar was flat.

On Our Radar: Analysts will be watching several key reports, including: initial jobless claims, GDP and pending homes sales. On the earnings front, all eyes will be on Dell (DELL) Marvell (MRVL), Autodesk (ADSK) and Affirm (AFRM), all of which will report results after the market close today.

MongoDB (MDB) soared 35% in its best session ever after posting a blowout quarter and raising full-year guidance. But that wasn’t the only big mover of the day…

Discover how the market is moving with our interactive heatmap. Filter by market cap, or click on any box to explore specific sectors or assets in more detail.

His Recent Winners = Years Of Membership

Matt Maley's August performance demonstrates why members stay year after year. Real-time alerts from a 35-year Wall Street veteran. Labor Day special: $799. Sale ends Monday.

On This Day In 1907…

James E. Casey founded the American Messenger Company in Seattle, laying the foundation for what would become UPS. Starting with just a bicycle and a phone, the company focused on reliable message and package delivery. Over time, it expanded, rebranded as United Parcel Service in 1919, and grew into one of the world’s largest logistics and delivery companies. Today, UPS has a market cap of $75 billion and delivers nearly 6 billion packages last year.

QUOTE OF THE DAY

“The best time to sell a stock is almost never.“ — Philip Fisher

Wall Street Has No Fear — But A Shocking Selloff Could Be Lurking

Wall Street is riding high with the S&P 500 rallying more than 35% and Nvidia doubling in value since April. Traders aren’t just optimistic — they’re betting heavily that volatility is a thing of the past.

In fact, short positions on the VIX have surged to levels not seen since 2021, signaling a market that’s convinced calm skies will continue. But history has a way of humbling even the most confident. And with September just around the corner — traditionally the worst month for stocks — the VIX could be on the upswing. Read on for all the details.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.

Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.